Abstract: Oyster has a variety of biological activities, and with the intensive research on the development of its activities, the great potential for the improvement of osteoporosis has been found. In this paper, the oyster enzymatic products (OP) were used to investigate their mitigating effects on glucocorticoid-type osteoporosis. A dexamethasone-induced glucocorticoids osteoporosis (GIOP) model was established, and different doses of OP were used to evaluate the mitigating effects of OP on the osteoporosis in rats in terms of serum biochemical indexes, Micro-CT, three-dimensional reconstruction, and histopathological sections. The results show that compared with the model group, the serum content of osteoprotegerin, Type I procollagen amino-terminal peptide and testosterone, which are the osteoclast markers, increased by an average of 13.67%, 11.51% and 17.80% in the low, medium and high dose groups, respectively (p<0.05); but the serum content of matrix metalloproteinases, histone K and anti-tartrate acid phosphatase, which are the osteoclast markers, decreased by 15.44%, 31.20% and 14.43%, respectively (p<0.05). The results of bone densitometry and histopathological analysis of Micro-CT and femur indicate that compared with those of the model group, the bone mineral density, the percentage of bone trabecular area and the area of bone salt deposition in the high-dose group increased by 56.31%, 18.59% and 22.51%, respectively (p<0.05). In conclusion, OP can accelerate the formation of new bone by increasing the ability of osteoblasts to synthesize collagen, decrease the rate of bone matrix degradation and bone metabolism, decrease the loss of bone mass, increase the level of sex hormones, increase the BMD, bone volume fraction, enhance the ability of bone to deposit bone calcium salts in rats, thus improve the symptoms of glucocorticoid-induced osteoporosis induced by dexamethasone.